"In oncology today, we are given great opportunities to make a lot of positive impact on the lives of our patients."
Alexey Danilov, M.D., Ph.D., chose oncology as a career because of its breadth and potential. Oncology, he says, "touches all areas of general medicine" and is a most exciting field because of the many new treatments now emerging.
A board-certified clinician and talented researcher, Dr. Danilov focuses on blood cancers, including chronic lymphocytic leukemia and many forms of lymphoma. He is a Leukemia & Lymphoma Society Scholar in Clinical Research.
A native of Russia, Dr. Danilov earned his medical degree and Ph.D. at Yaroslavl State Medical Academy. He continued his training with a residency at Brown University in Providence, Rhode Island, and a fellowship at Tufts Medical Center in Boston.
In his role of an Associate Director, Toni Stephenson Lymphoma Center at City of Hope, Dr. Danilov directs an effort in experimental therapeutics in B-cell malignancies. He received peer-reviewed funding from the National Cancer Institute, Leukemia and Lymphoma Society, American Society of Hematology, and Lymphoma Research Foundation, and serves as Translational Medicine Chair of the SWOG Lymphoma Committee, thus participating in drug discovery on a global scale.
An ideal fit for City of Hope, Dr. Danilov's lab is funded by the National Cancer Institute, Leukemia and Lymphoma Society and American Society of Hematology and concentrates on "bench to bedside" medicine, where preclinical findings lead to early phase clinical trials, ultimately translating into real treatments for real patients.
2012, American Board of Internal Medicine, Hematology
2010, American Board of Internal Medicine, Medical Oncology
2007, American Board of Internal Medicine, Internal Medicine
2000, Ph.D., Yaroslavl Medical Academy, Russia
1997, M.D., summa cum laude, Yaroslavl Medical Academy, Russia
2007-2010, Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts
2004-2007, Medicine, Brown University School of Medicine, Providence, Rhode Island
2004-2005, Medicine, Brown University School of Medicine, Providence, RI
2020-Present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Associate Director, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
2020-Present, Translational Medicine Chair, SWOG Lymphoma
2014-2020, Assistant & Associate Professor of Medicine, Hematology - Oncology, OHSU, Portland, OR
2010-2014, Assistant Professor of Medicine, Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2001-2004, Research Scholar, Tufts University School of Medicine, Boston, MA
2000-2001, Instructor, Department of Medicine, Yaroslavl Medical Academy, Russia
1998-1999, Instructor, Department of Pathophysiology, Yaroslavl Medical Academy, Russia
The Danilov Lab focuses its attention on drug resistance in lymphoma, with emphasis on key signaling pathways (TNF receptor and NFκB signaling). Using stromal co-cultures, the Danilov lab models the tumor-supportive microenvironment in vitro, as well as studies drug resistant tumors in vivo. The lab has a track record investigating the function of the ubiquitin-proteasome system in cancer, and has studied proximal components of the UPS (E1 enzymes) as therapeutic targets in lymphoma. Moreover, the lab recently set out to advance understanding of the effect of targeted therapies on T cell function, thus hoping to inform progress in immuno-oncology.
2014, Lymphoma Research Foundation Clinical Investigator
2013, Best Abstract, Young Investigator/XV International Workshop on CLL, Köln/Germany
2013, Gazzaniga Family Prize for outstanding research at Dartmouth (Thesis Advisor to L.A.Humphries)
2012, Abstract Achievement Award, 54th ASH Annual Meeting (Humphries & Danilov)
2012, Participant, ASH Clinical Research Training Institute, La Jolla, CA
2010, Excellence in Teaching Award, Medicine, Dartmouth-Hitchcock Medical Center
2017, Member, SWOG CLL Study Group
2016, Member, SWOG Leukemia Working Group
2014, Member, SWOG Lymphoma Working Group
Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, Spurgeon S and Danilov AV. 2021. Entospletinib and obinutuzumab in patients with relapsed/refractory CLL and B-cell malignancies. Haematologica. doi: 10.3324/haematol.2020.270298.
Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, Murray S, Berger A, Pennock ND, Lind EF and Danilov AV. 2021. Immunomodulatory effects of pevonedistat, a Nedd8-activating enzyme inhibitor, in CLL. Leukemia. 35(1): 156-168.
Danilov AV, Persky DO. 2021. Incorporating acalabrutinib, a next-generation selective BTK inhibitor, into clinical practice for the treatment of hematologic malignancies. 2020. British Journal of Haematology. https://doi.org/10.1111/bjh.17184.
Evens AM, Danilov AV, …, Olszewski AJ and Alderuccio JP. 2021. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. Blood. 137(3); 374-386.
Gordon MJ, Huang J, Chan RJ, Bhargava P and Danilov AV. 2021. Medical comorbidities in patients with chronic lymphocytic leukemia treated with idelalisib: analysis of two large randomized clinical trials. British J Haemtol. 192(4): 720-728.
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D and Brown JR. 2021. A Phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI836826, in combination with ibrutinib in patients with relapsed/refractory CLL. Invest New Drugs. doi: 10.1007/s10637-020-01056-4
Danilov AV, Herbaux C, Walter H, Hillmen P, Rule S, Kio EA, Karlin L, Dyer MJ, Mitra S, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jurgensmeier JM and Fegan C. 2020. Phase 1b study of tirabrutinib alone or in combination with idelalisib or entospletinib in previously treated CLL. Clinical Cancer Research. 26 (12): 2810-2818.
Sharman J, Yimer H, Boxer M, Di Bella N, Babu S, Li J, Mun Y and Danilov AV. 2020. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with CLL. Leukemia & Lymphoma. In press.
Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV and Tyner JW. 2020. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Nature Leukemia. doi: 10.1038/s41375-020-0764-6.
Best SR, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A and Danilov AV. 2019. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances. 3(1): 51-62.
Hashiguchi T, Bruss N, Best S, Lam V, Danilova OV, Paiva C, Wolf J, Gilbert E, Okada C, Kaur P, Drew L, Cidado J, Hurlin P and Danilov AV. 2019. Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma. Molecular Cancer Therapeutics. 18(9): 1520-1532.
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’Alessandro A, Culp-Hill R, d’Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK and Tyner JW. 2019. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discovery. 9 (7): 910-925.
Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D and Danilov AV. 2018. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15): 3192-3200.
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Reister-Shulz A, Traer E, Abel M, ….., Danilov AV, ….., Druker BD. 2018. Functional genomic landscape of acute myeloid leukemia. Nature. doi: 10.1038/s41586-018-0623-z
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Show respect for what you say
Provider listen carefully to you
Know important info medical history
Spend enough time with you
Recommend this provider office
Provider explain in way you understand
Rate provider 0-10
I hope I can put very good when the treatment is finished. - Verified patient
I was very happy with the service I received. - Verified patient
My experience was very positive I will recommend it to anyone. - Verified patient
Dr. Alexy is wonderful, smart, practical and really knows his stuff - Verified patient
Great and knowledgeable doctor Danilov - Verified patient